Innovative Drug European Associates
Innovative Drug European Associates
IDEA is as passionate as you about your product. We understand the art and science of regulatory approval, and can help you devise a regulatory and reimbursement strategy that could be the critical difference in ensuring your product reaches as many of the needs of patients as possible across the globe.
IDEA understands the needs to today’s busy clinicians. We understand that you want to focus your efforts where it really matters – on making a difference for your patients. But running trials of innovative new treatments with the needs of patients, collating strong data and publishing results needs a solid regulatory framework.
European regulatory systems are complex and highly demanding. For CRO’s, especially those outside Europe, navigating the complex country-specific legal and regulatory requirements is a significant challenge. IDEA is able to provide EU legal representation and regulatory assistance to help CROs understand how to maximise access.
Despite having talented teams, small companies are forced to work with limited resources and access to specific expertise. They often lack the resources and experience in navigating specific regulations, the nuances of working in different countries and have limited time to spend on regulatory intelligence. Working with a regulatory expert who is familiar with your […]
The global coronavirus pandemic, or COVID-19, has brought about both a health crisis as well as personal and business uncertainty. Yet bringing new life saving and life changing products to market remains a pressing priority. Patients are waiting for cures and their needs cannot be postponed. As a leader in providing regulatory affairs expertise and […]
There is much talk today about patient-centricity in the clinical trials, from discussions about how to ease the burden for patients, to how to empower and engage patients. But to my mind a central aspect of patient centricity that is poorly addressed is how patients and advocacy groups get better access to medical research, or […]
